These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8985471)

  • 21. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
    Goldberg TE; Goldman RS; Burdick KE; Malhotra AK; Lencz T; Patel RC; Woerner MG; Schooler NR; Kane JM; Robinson DG
    Arch Gen Psychiatry; 2007 Oct; 64(10):1115-22. PubMed ID: 17909123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact on cognition of the use of antipsychotics.
    Sharma T
    Curr Med Res Opin; 2002; 18 Suppl 3():s13-7. PubMed ID: 12418607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication.
    Moritz S; Woodward TS; Krausz M; Naber D;
    Int Clin Psychopharmacol; 2002 Jan; 17(1):41-4. PubMed ID: 11800506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive effects and antipsychotic treatment.
    Kasper S; Resinger E
    Psychoneuroendocrinology; 2003 Jan; 28 Suppl 1():27-38. PubMed ID: 12504070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tolerance of neuroleptics, deficit syndrome and cognitive functions].
    Kahn JP
    Encephale; 1996 Jun; 22 Spec No 2():49-54. PubMed ID: 8767043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
    Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
    Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life".
    Monteleone P; Cascino G; Monteleone AM; Rocca P; Rossi A; Bertolino A; Aguglia E; Amore M; Collantoni E; Corrivetti G; Cuomo A; Bellomo A; D'Ambrosio E; Dell'Osso L; Frascarelli M; Giordano GM; Giuliani L; Marchesi C; Montemagni C; Oldani L; Pinna F; Pompili M; Roncone R; Rossi R; Siracusano A; Vita A; Zeppegno P; Galderisi S; Maj M;
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110250. PubMed ID: 33484755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.
    Keefe RS; Silva SG; Perkins DO; Lieberman JA
    Schizophr Bull; 1999; 25(2):201-22. PubMed ID: 10416727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
    Bilder RM; Goldman RS; Volavka J; Czobor P; Hoptman M; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Kunz M; Chakos M; Cooper TB; Horowitz TL; Lieberman JA
    Am J Psychiatry; 2002 Jun; 159(6):1018-28. PubMed ID: 12042192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone.
    Tracy JI; Monaco CA; Abraham G; Josiassen RC; Pollock BG
    J Clin Psychiatry; 1998 Apr; 59(4):184-8. PubMed ID: 9590669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
    Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy.
    Stip E
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S27-34. PubMed ID: 8899248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment.
    Velligan DI; Miller AL
    J Clin Psychiatry; 1999; 60 Suppl 23():25-8. PubMed ID: 10625197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.
    Mulsant BH; Gharabawi GM; Bossie CA; Mao L; Martinez RA; Tune LE; Greenspan AJ; Bastean JN; Pollock BG
    J Clin Psychiatry; 2004 Dec; 65(12):1708-14. PubMed ID: 15641877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia.
    Maat A; Cahn W; Gijsman HJ; Hovens JE; Kahn RS; Aleman A
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):575-84. PubMed ID: 24418213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
    J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning.
    Harvey PD; Patterson TL; Potter LS; Zhong K; Brecher M
    Am J Psychiatry; 2006 Nov; 163(11):1918-25. PubMed ID: 17074943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.